北京若生智能科技有限公司
Drug Database
DE

delivery technology (CEFORM EA / CEFORM RA / CEFORM)

✓ Approved

Bausch Health Companies Inc. · 治疗药物

什么是 delivery technology？

delivery technology 是一种治疗药物，由Bausch Health Companies Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名CEFORM EA, CEFORM RA, CEFORM
公司Bausch Health Companies Inc.
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Bausch Health Companies Inc.

治疗适应症

delivery technology 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedNanomedicine (London, England)2026-09-10

CRISPR-Cas9‑based lipid nanocarriers for advanced therapy of urinary bladder cancer.

Mukherjee Swarupananda S, Karati Dipanjan D, Sarkar Sinjini S, Ash Dipanjana D et al.

Bladder cancer (BCa) exhibits significant genetic and phenotypic variability. This variability suggests that various tumor subtypes could be influenced by several biomarkers and signaling pathways, which presents a problem for monotherapy strategies. Despite the initial effectiveness of traditional therapies, BCa's high rates of progression and recurrence, and the eventual development of drug resistance in many patients, continue to be major concerns. Because of the potential to transform the genetic modifications linked to the disease, genome editing using CRISPR/Cas9 has become a transformative tool in medicine with noteworthy potential for BCa therapy. Although the CRISPR/Cas9 technology is incredibly effective at transforming the field of genome editing, its instability and cellular impermeability pose significant challenges to its delivery. To increase efficient delivery of CRISPR/Cas9, nanovectors may be investigated. Significant promise exists for improving the therapeutic potential of CRISPR-Cas9 technology and addressing complex cancer therapy difficulties because of the rapid development of nanotechnology-based delivery systems. Relevant articles were searched in Google Scholar, Scopus, and Web of Science covering studies published between 2007 and 2026. Along with the impact of lipid-based nanoparticles on their safe transport to cancer cells, this review emphasizes the significance of the CRISPR/Cas9 genome editing system in the treatment of BCa.

PMID 42720610
阅读全文 →
PubMedChemical record (New York, N.Y.)2026-09-10

From Barrier Disruption to Precision Skin Interface Engineering: Next-Generation Transdermal Drug Delivery.

Zhou Cong-Zheng CZ, Lin Xin-Yu XY, Yu Shou-Shan SS, Qiao Sheng-Lin SL

Transdermal drug delivery (TDD) is reemerging as a clinically attractive route for noninvasive therapy, driven by the growing demand for alternatives to repeated injection and by the rapid development of materials capable of regulating transport across the skin. By avoiding gastrointestinal degradation and hepatic first-pass metabolism, TDD can provide prolonged drug exposure, reduce peak-to-trough fluctuations in plasma concentration, and improve adherence in long-term treatment. Its broader implementation, however, is still constrained by the exceptional barrier function of the stratum corneum, which severely limits the passive transport of hydrophilic molecules, charged species, and macromolecular therapeutics. In this review, we critically discuss the structural basis of the skin barrier and summarize the evolution of TDD strategies from conventional chemical permeation enhancement and device-assisted physical disruption to nanocarrier-mediated, biomimetic, and intelligent bio-delivery systems. Particular emphasis is placed on the mechanistic logic that connects carrier composition, interfacial interactions, skin microenvironment remodeling, and therapeutic performance. Representative examples are analyzed to highlight both opportunities and translational bottlenecks. Finally, we outline future directions in multimodal delivery, pathology-adapted design, standardized evaluation, and scalable manufacturing, which will be essential for transforming TDD from a permeability enhancement technology into a precision-regulated therapeutic platform.

PMID 42717625
阅读全文 →
PubMedBlockchain in healthcare today2026-09-10

Opportunities and Risks of Technology Convergence in Precision Health.

Vasiliu-Feltes Ingrid I, Bustamante Carlos D CD, Bischof Evelyne E, Dennis Stephen J SJ

This ConV2X Decentralized Health 2026 executive roundtable explores how technology convergence impacts precision health outcomes. The dialogue focuses on the main technologies supporting precision health, the latest scientific developments, technology advancements, opportunities, and risks. It is moderated by BHTY journal editor Prof. Dr. Vasiliu-Feltes. Participants emphasize the latest scientific developments, opportunities, and risks associated with precision health, enabled by converging advanced technologies.

PMID 42719251
阅读全文 →
PubMedAAPS PharmSciTech2026-09-10

From Liquid to Gel: Multifunctional Stimuli-responsive Polymers for Targeted Oral Drug Delivery.

Mishra Manoj Kumar MK, Shukla Divaker D, Sharma Shalini S, Sharma Jyoti Nanda JN et al.

Oral drug delivery is the delivery method of choice, as it is non-invasive and patients will comply with the delivery method, but many contemporary therapeutics, such as poorly soluble, permeable, and unstable drugs, fail because of rapid gastrointestinal absorption, enzyme degradation, and non-targetability. The in-situ gelling systems are now considered paradigms that no longer exist as liquids; instead, they form a depot in the gastrointestinal tract and transform into a gel in response to physiological signals such as pH, ions, or enzymes. This review will discuss how these so-called smart polymers have developed over the years, starting as simple gel-forming systems and evolving into the multifunctional platforms that are also designed to have a pointed and sustained action. Next generation in situ gels combine bioadhesion, permeation enhancement, and active targeting ligands to overcome sequential barriers to delivery transit, permeability, stability, and cellular uptake. We critically assess the chemistry, mechanisms, formulation strategies, and therapeutic use of these systems, including gastro-retention and localized therapy, as well as oral delivery of biologics. Despite encouraging preclinical results, we touch on translational issues of scalability, manufacturing, and regulatory pathways. Multifunctional stimuli-responsive polymers, which actively traverse the gastrointestinal environment, are the future of oral drug delivery because they provide precision, bioavailability, and improved patient outcomes.

PMID 42717126
阅读全文 →
PubMedRSC pharmaceutics2026-09-10

Nose-to-brain delivery of IRX4204 by cell-adhesion peptide-functionalized gemini surfactant-phospholipid nanoparticles.

Hakim Antoine A, Kasheke Gracious D S GDS, Robertson George S GS, Foldvari Marianna M

Efficient delivery of hydrophobic therapeutics to the central nervous system (CNS) remains challenging due to poor solubility, limited blood-brain barrier permeability and systemic toxicity. Here, we report the development of gemini surfactant-phospholipid nanoparticles (GPNPs) for intranasal delivery of the highly potent and preferential retinoid X receptor agonist IRX4204. Physicochemical characterization demonstrated stable nanoparticles (60 nm, +40 mV) with high encapsulation efficiency and long-term stability. Dynamic light scattering, transmission electron microscopy and small-angle X-ray scattering revealed that optimal drug loading in GPNPs is ≤0.5 mg mL-1. The formulations showed the coexistence of two structurally distinct particle populations, flattened micelles and larger vesicular structures. In vivo studies in mice demonstrated that intranasal administration of IRX4204-GPNPs (0.12 mg kg-1) achieved higher CNS concentrations than a 100-fold higher oral dose (12 mg kg-1), with sustained distribution across various CNS regions and enhanced striatal accumulation. Compared to oral IRX4204 suspension administration, intranasal delivery of IRX4204-GPNPs achieved about 1.4-fold higher CNS drug concentrations, 136-fold greater delivery efficiency (0.19% vs. 0.0014% of dose) and 73.5% direct transport percentage (DTP), accompanied by markedly reduced plasma and liver exposure. Pharmacodynamic evaluation confirmed sustained activation of RXR-responsive genes, including SCD1 and LXRα, following intranasal nanoparticle delivery. These findings demonstrate that optimized GPNPs enable efficient CNS targeting and support their use as a promising intranasal platform for delivery of RXR agonists and other hydrophobic therapeutics.

PMID 42719635
阅读全文 →
PubMedInternational journal of women's health2026-09-10

Correlation Between Placental Calcification, Umbilical Artery Hemodynamic Parameters and Delivery Outcomes in Patients with Gestational Diabetes.

Chen Hongjing H, Gu Qiang Q, Qian Linyu L, Wang Fang F

To investigate the correlation between the degree of placental calcification, umbilical artery hemodynamic parameters, and delivery outcomes in patients with gestational diabetes mellitus (GDM). A total of 190 GDM patients admitted to our hospital were retrospectively selected as the research subjects; gestational weeks ranged from 28 to 42. According to the placental calcification degree detected by ultrasound before delivery, they were divided into Grade 0 (n=62), Grade I (n=58), Grade II (n=45), and Grade III (n=25). Clinical data of all subjects were collected, and the umbilical artery hemodynamic parameters [systolic peak velocity/end-diastolic velocity (S/D), resistance index (RI), pulsatility index (PI)] and delivery outcome-related indicators were compared among groups. Spearman rank correlation analysis was used to explore the correlation between placental calcification degree and umbilical artery hemodynamic parameters. Multivariate Logistic regression analysis was used to screen independent risk factors for adverse delivery outcomes in patients with GDM. There were significant differences in umbilical artery S/D, RI and PI among patients with different placental calcification degrees (F=108.75, 82.73, 158.20, all P<0.001). Spearman rank correlation analysis showed that placental calcification degree was positively correlated with umbilical artery S/D, RI and PI in patients with GDM (r=0.760, 0.730, 0.817, all P<0.001). There were statistically significant differences in cesarean section rate, preterm delivery rate, fetal distress rate and macrosomia rate among groups (χ2=42.984, 16.052, 47.556, 11.798, all P<0.001). Multivariate Logistic regression analysis showed that Grade II placental calcification, Grade III placental calcification, and umbilical artery S/D ≥3.0 were independent risk factors for adverse delivery outcomes in patients with GDM. Placental calcification degree was closely correlated with umbilical artery hemodynamic parameters in patients with GDM. Grade II and Grade III placental calcification and umbilical artery S/D ≥3.0 could all affect the occurrence of adverse delivery outcomes in patients with GDM.

PMID 42719825
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多delivery technology